# The Binding of Brazilin from C. sappan to the Full-Length SARS-CoV-2 Spike Proteins

**Authors:** Phonphiphat Bamrung, Borvornwat Toviwek, Firdaus Samsudin, Phoom Chairatana, Peter John Bond, Prapasiri Pongprayoon

PMC · DOI: 10.3390/ijms26094100 · 2025-04-25

## TL;DR

This study explores how a compound from the C. sappan plant interacts with the SARS-CoV-2 spike protein, suggesting it could be a potential treatment for COVID-19.

## Contribution

The study reveals the binding mechanism of BRA to the SARS-CoV-2 spike protein and its stability in different protein constructs.

## Key findings

- BRA binds stably to the receptor-binding motif on the RBD surface.
- Glycosylation does not affect BRA binding due to its distant binding site from glycans.
- BRA is bound by residues near the S1/S2 interface but cannot fit into the MM pocket.

## Abstract

The emergence of coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become a global issue since 2019. The prominent characteristic of SARS-CoV-2 is the presence of the spike (S) protein protruding from the virus particle envelope. The S protein is a major drug and vaccine target because it initiates the key step in infection. Medicinal herbs are a potential treatment option to enhance immunity to fight viral infections. Caesalpinia sappan L. has been reported to display promising anti-viral activities. Specifically, brazilin (BRA), a major bioactive compound in C. sappan, was reported to play a role in inhibiting viral infection. Thus, the ability of BRA as a COVID-19 treatment was tested. The S protein was used as the BRA target of this work. Understanding the binding mechanism of BRA to the S protein is crucial for future utilisation of C. sappan as a COVID-19 treatment or other coronavirus-caused pandemics. Here, we performed molecular docking of BRA onto the S protein receptor binding domain (RBD) and multimerisation (MM) pockets. Molecular dynamics (MD) simulations were conducted to study the stability of binding to glycosylated and non-glycosylated S protein constructs. BRA can bind to the Receptor-binding motif (RBM) on an RBD surface stably; however, it is too large to fit into the MM pocket, resulting in dissociation. Nonetheless, BRA is bound by residues near the S1/S2 interface. We found that glycosylation has no effect on BRA binding, as the proposed binding site is far from any glycans. Our results thus indicate that C. sappan may act as a promising preventive and therapeutic alternative for COVID-19 treatment.

## Linked entities

- **Proteins:** LOC102617969 (S-protein homolog 24-like), l(3)62Bi (lethal (3) 62Bi)
- **Chemicals:** brazilin (PubChem CID 73384), BRA (PubChem CID 1491)
- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, VTN (vitronectin) [NCBI Gene 7448] {aka V75, VN, VNT}
- **Diseases:** infection (MESH:D007239), viral infection (MESH:D014777), COVID-19 (MESH:D000086382), coronavirus (MESH:D018352)
- **Chemicals:** glycans (MESH:D011134), BRA (MESH:C044362)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Biancaea sappan (Indian redwood, species) [taxon 483143]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12072004/full.md

---
Source: https://tomesphere.com/paper/PMC12072004